Silo Pharma, Inc. Logo

Silo Pharma, Inc.

Develops novel psychedelic & traditional therapies for pain and central nervous system disorders.

SILO | US

Overview

Corporate Details

ISIN(s):
US82711P2011 (+1 more)
LEI:
Country:
United States of America
Address:
677 N. WASHINGTON BLVD, 34236 SARASOTA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on creating novel formulations of traditional and psychedelic therapeutics. The company targets underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Its portfolio includes programs such as SPC-15 for PTSD and SP-26 for fibromyalgia, as well as preclinical assets for Alzheimer’s disease and multiple sclerosis. Silo Pharma utilizes the streamlined 505(b)(2) regulatory pathway to potentially lower costs and accelerate FDA approval. The company develops its intellectual property through exclusive collaborations with leading universities and research partners.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Silo Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Silo Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Silo Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.